Key Highlights

- Experienced pharma executive, Dr Beata Niechoda, joins Noxopharm Board
- Mr John Moore becomes Executive Chairman of Noxopharm spin-off, Nyrada
- Nyrada Board expanded with the addition of 2 international directors

Sydney, 16 July 2019: Following the recent move of Graham Kelly from CEO to Executive Chairman, Noxopharm Ltd (‘Noxopharm’) (ASX:NOX) is pleased to announce a series of further planned changes in Board membership for both itself and its subsidiary company, Nyrada Inc. (‘Nyrada’). The changes reflect the considerable progress being made in the businesses of both companies, their growing independence from each other, and plans for future listings on security exchanges.

Noxopharm Board and Dr Beata Niechoda
Over the past 6 months, Dr Niechoda has served as a Special Advisor to the Noxopharm Board, providing the Board with independent advice on the Company’s clinical and commercial strategies and objectives.

Dr Niechoda holds medical qualifications, a PhD and an MBA, and is Australian Health Practitioner Regulation Agency (AHPRA) registered. She has held senior positions in global pharmaceutical companies including Medical Director Shire Australia (2010-2014), Senior Medical Director Eli Lilly ANZ (2014-2017) and Executive Medical Director Amgen ANZ (2017-2018).

Dr Niechoda brings a wealth of experience in healthcare and the pharmaceutical industry, with specific expertise in clinical development, product launches, medical strategy and change management. The Noxopharm Board considered it was important to add to its breadth of expertise in light of its growing confidence in the Company becoming a major player in oncology. Dr Niechoda’s acceptance of the offer to join the Board reflects her confidence in the future of the Company.
In addition to Board duties, Dr Niechoda will work closely with the Company’s CEO, Dr Greg van Wyk, and the Company’s Global Medical Director, Dr Gisela Mautner, providing a high-level executive team with broad industry experience driving the Veyonda® drug development program and commercial strategy.

The Noxopharm Board now is:
Dr Graham Kelly Executive Chairman
Mr Peter Marks Non-Executive Director and Deputy Chairman
Dr Beata Niechoda Non-Executive Director
Dr Ian Dixon Non-Executive Director

Nyrada Board
Nyrada has expanded its Board in preparation for it seeking a listing on a public exchange, its strategy of raising its profile globally, and its financial separation from parent company, Noxopharm.

(a) Mr John Moore
The first appointment is Mr John Moore as Executive Chairman. John joined the Noxopharm Board in 2018, where in addition to his general Board duties, he has been working closely with Dr Kelly in preparing Nyrada for a public listing. Having become engaged in the Nyrada business, Mr Moore has resigned as a director of Noxopharm and has moved from being a Noxopharm nominee on the Nyrada Board to be an independent director.

Mr Moore, who is a U.S. citizen, will serve as Executive Chairman of Nyrada, assisting Dr Kelly in the aim of listing Nyrada in a non-U.S. territory in 2019 and then the U.S. in 2020.

John Moore said, "Small companies like Nyrada have always been the source of major innovation in the pharmaceutical business but they often lack the human resources to convert their innovation into commercial success. I am pleased to have recruited two of the most talented people I know in Marcus and Rüdinger in capital markets and business development respectively. I have always believed a great Board is a tribute to the mission of the business they serve."

(b) Mr Marcus Frampton
Marcus serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation, the $65 billion sovereign wealth fund for the State of Alaska (APFC). Marcus manages the investment team at APFC and leads all investment decisions related to the APFC’s investment portfolio. Marcus graduated from UCLA with a bachelor’s degree in Business-Economics and a Minor in Accounting.
Dr Rüdiger Weseloh

Rüdiger serves as a Senior Director in Business Development at Merck KGaA, Darmstadt, Germany. Rüdiger has led more than 50 transactions for its pharmaceutical division in the fields of Oncology, Rheumatology, Neurodegenerative Diseases, and Fertility. Before Merck KGaA, Rüdiger spent 5 years as a biotech/pharma equity analyst at Gontard & Metallbank, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, and 3 years at the Max-Planck-Institute for Experimental Medicine in Göttingen. He has a university diploma in Biochemistry from the University of Hannover and a PhD in Molecular Neurobiology obtained at the Center for Molecular Neurobiology in Hamburg.

The Nyrada Board now is:
Mr John Moore          Executive Chairman. Independent
Dr Graham Kelly        Executive Director and President. Non-independent
Mr Peter Marks         Non-Executive Director. Non-independent
Mr Marcus Frampton     Non-Executive Director. Independent
Dr Rüdiger Weseloh     Non-Executive Director. Independent

Noxopharm Chairman Comments
Noxopharm Executive Chairman, Dr Graham Kelly, welcomed the appointment of Dr Niechoda, saying, “Dr Niechoda’s invitation to join the NOX Board reflects the Company’s evolution from listing as an early-stage clinical company when it listed, into its profile now as a biopharmaceutical company with an exciting future ahead of it.”

Dr Kelly said, “The experience that Beata brings gives the Board the necessary expertise it needs to provide even more effective integration with the Company’s experienced executive team. Together they will work on bringing Veyonda® to market as quickly as possible. Beata has established her value to the Board these past 6 months as a special advisor, and it is a pleasure to have that expertise on the Board. Combined with our CEO, Dr Greg van Wyk and his clinical team, I am satisfied that Veyonda now is in good hands as it moves towards its final stages of testing.”

“Noxopharm has two valuable assets - Veyonda® and its majority shareholding in Nyrada. In Nyrada, Noxopharm shareholders have a major stake in a company that the Noxopharm Board sees as having significant commercial potential. Nyrada is researching and developing assets which include a first-in-class drug candidate intended to help lower blood cholesterol levels in the 50% of patients who fail to respond adequately to statin drugs. That market already has been identified as having a potential annual value of $10 billion. A second drug candidate, also first-in-class, is designed to protect the brain from damage associated with stroke and traumatic brain injury such as concussion. The growing awareness of the need to protect athletes from long-term consequences of concussion such as that suffered by footballers and leading to a current US$517 million pay-out by the NFL, highlights just one of many reasons for the Nyrada Board’s confidence in the Company’s prospects,” Kelly added.
Dr Kelly said, “John Moore brings a wealth of entrepreneurial, advisory and M&A experience in the healthcare field that will be invaluable in growing Nyrada and thereby contribute to the growing value of Noxopharm.”

About Noxopharm
Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc

About Nyrada
Nyrada is a U.S.-registered drug development company with 4 small molecule R&D programs; (i) a PCSK9 inhibitor, (ii) a neuroprotectant drug, (iii) an anti-inflammatory/analgesic for peripheral neuropathy, and (iv) an IRAK4 inhibitor for autoimmune diseases.

www.noxopharm.com

Investor & Corporate Enquiries:  Company Secretary:
Prue Kelly  David Franks
M: 0459 022 445  T: +61 2 9299 9690
E: info@noxopharm.com  E: David.Franks@automicgroup.com.au

Media Contact:
Cherilyn Cecchini, M.D.
LifeSci Public Relations
T: +1 646 876 5196
E: ccecchini@lifescipublicrelations.com

Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.